InvestSMART

Argenica Therapeutics Limited (ASX: AGN) - Announcements

- Current share price for AGN : $0.097

ASX company news and announcements for Argenica Therapeutics Limited (AGN) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Argenica Therapeutics Limited (AGN) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Argenica Therapeutics Limited (AGN), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Argenica Therapeutics Limited (AGN)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$12 Investor Webinar 11 Jun 2026 8:33AM $0.110 $0.097 fallen by 11.82%
$12 Investor Presentation 11 Jun 2026 8:33AM $0.110 $0.097 fallen by 11.82%
$12 ARG007 (Xaranetide) Completes All Three FDA Requested Assays 11 Jun 2026 8:33AM $0.110 $0.097 fallen by 11.82%
$12 WHO Confirms Xaranetide as INN for ARG-007 10 Jun 2026 8:19AM $0.115 $0.097 fallen by 15.65%
$12 Notification of cessation of securities - AGN 9 Jun 2026 2:13PM $0.115 $0.097 fallen by 15.65%
$12 Release of Securities from Voluntary Escrow 26 May 2026 9:52AM $0.115 $0.097 fallen by 15.65%
$12 IND Application Advanced With Successful Completion of Assay 21 May 2026 9:01AM $0.135 $0.097 fallen by 28.15%
$12 Clinical Advisory Committee Established to Advance Phase 2b 14 May 2026 9:15AM $0.150 $0.097 fallen by 35.33%
$12 Quarterly Activities/Appendix 4C Cash Flow Report 29 Apr 2026 8:20AM $0.180 $0.097 fallen by 46.11%
$12 Investor Presentation - Ignite Conference 16 Apr 2026 9:15AM $0.160 $0.097 fallen by 39.38%
$12 Presentations at European Stroke Organisation Conference 26 Mar 2026 8:13AM $0.165 $0.097 fallen by 41.21%
$12 Argenica Receives $3.97m R&D Tax Incentive Cash Rebate 17 Mar 2026 8:19AM $0.200 $0.097 fallen by 51.50%
$12 Half Yearly Report and Accounts 11 Feb 2026 8:17AM $0.285 $0.097 fallen by 65.96%
$12 Investor Presentation - Euroz Hartleys Healthcare Conference 5 Feb 2026 8:23AM $0.290 $0.097 fallen by 66.55%
$12 Successful Applicaton for EMA Paediatric Waiver 2 Feb 2026 9:01AM $0.280 $0.097 fallen by 65.36%
$12 Quarterly Activities/Appendix 4C Cash Flow Report 28 Jan 2026 8:15AM $0.255 $0.097 fallen by 61.96%
$12 Final Director's Interest Notice 2 Jan 2026 4:53PM $0.305 $0.097 fallen by 68.20%
$12 Non-Executive Chair Resignation 29 Dec 2025 8:27AM $0.270 $0.097 fallen by 64.07%
$12 AI Analysis Reveals Efficacy In Severe Stroke Patients 11 Dec 2025 9:11AM $0.270 $0.097 fallen by 64.07%
$12 Positive TNK Study Results Fulfil Key FDA Requirement 4 Dec 2025 8:17AM $0.220 $0.097 fallen by 55.91%
$12 ARG-007 Efficacious Dose Validated in New Preclinical Study 25 Nov 2025 9:16AM $0.220 $0.097 fallen by 55.91%
$12 Final Director's Interest Notice 12 Nov 2025 7:05PM $0.255 $0.097 fallen by 61.96%
$12 Results of Annual General Meeting 12 Nov 2025 7:03PM $0.255 $0.097 fallen by 61.96%
$12 AGM Chair's Address & Presentation 12 Nov 2025 4:53PM $0.255 $0.097 fallen by 61.96%
$12 Non-Executive Director Retirement 12 Nov 2025 4:49PM $0.255 $0.097 fallen by 61.96%

1 - 25 of 288 results

Page 1 of 12

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.